MX2023009630A - Composiciones en disolución acuosa para aumentar la estabilidad de las proteínas diméricas manipuladas genéticamente. - Google Patents

Composiciones en disolución acuosa para aumentar la estabilidad de las proteínas diméricas manipuladas genéticamente.

Info

Publication number
MX2023009630A
MX2023009630A MX2023009630A MX2023009630A MX2023009630A MX 2023009630 A MX2023009630 A MX 2023009630A MX 2023009630 A MX2023009630 A MX 2023009630A MX 2023009630 A MX2023009630 A MX 2023009630A MX 2023009630 A MX2023009630 A MX 2023009630A
Authority
MX
Mexico
Prior art keywords
aqueous solution
solution compositions
polypeptide
dimeric proteins
engineered dimeric
Prior art date
Application number
MX2023009630A
Other languages
English (en)
Inventor
Bradley Hayes
Brian Lobo
David Gerring
Jan Jezek
Ashraf Amanullah
Joshua Cremin
Jorge Pinto
Original Assignee
Arecor Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arecor Ltd filed Critical Arecor Ltd
Publication of MX2023009630A publication Critical patent/MX2023009630A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente solicitud se relaciona con composiciones en disolución acuosa de proteínas diméricas manipuladas genéticamente que comprenden monómeros que contienen al menos un polipéptido de serpina humana unido operativamente a un polipéptido humano de Fc de inmunoglobulina o a un polipéptido derivado de un polipéptido Fc de inmunoglobulina, a bajas concentraciones de soluciones amortiguadoras y baja fuerza iónica, y que contienen un aminoácido neutral. Las composiciones en disolución acuosa aumentan la estabilidad del dominio Fc en composiciones en disolución acuosa, y en particular aumentan la estabilidad de una proteína dimérica manipulada genéticamente.
MX2023009630A 2021-02-17 2022-02-17 Composiciones en disolución acuosa para aumentar la estabilidad de las proteínas diméricas manipuladas genéticamente. MX2023009630A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2102258.7A GB202102258D0 (en) 2021-02-17 2021-02-17 Novel composition
PCT/US2022/016864 WO2022178175A1 (en) 2021-02-17 2022-02-17 Aqueous solution compositions for increasing stability of engineered dimeric proteins

Publications (1)

Publication Number Publication Date
MX2023009630A true MX2023009630A (es) 2023-11-06

Family

ID=75338972

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023009630A MX2023009630A (es) 2021-02-17 2022-02-17 Composiciones en disolución acuosa para aumentar la estabilidad de las proteínas diméricas manipuladas genéticamente.

Country Status (12)

Country Link
US (1) US20220265788A1 (es)
EP (1) EP4294372A1 (es)
JP (1) JP2024506718A (es)
KR (1) KR20230147140A (es)
CN (1) CN117279624A (es)
AU (1) AU2022224607A1 (es)
BR (1) BR112023016442A2 (es)
CA (1) CA3208704A1 (es)
GB (1) GB202102258D0 (es)
IL (1) IL305142A (es)
MX (1) MX2023009630A (es)
WO (1) WO2022178175A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023225513A1 (en) * 2022-05-16 2023-11-23 Inhibrx, Inc. Effective dosage of recombinant serpin-fc fusion protein for use in a method of treating aat deficiency in a subject

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004216298B2 (en) * 2003-02-28 2009-04-23 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations
JP2007511539A (ja) * 2003-11-14 2007-05-10 バクスター・インターナショナル・インコーポレイテッド α１−抗トリプシン組成物およびこのような組成物を用いた処置方法
EP1789434B1 (en) * 2004-08-31 2013-11-20 Novo Nordisk A/S Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
SG162788A1 (en) * 2005-06-14 2010-07-29 Amgen Inc Self-buffering protein formulations
GB0700523D0 (en) * 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
US20130209465A1 (en) * 2010-07-30 2013-08-15 Arecor Ltd. Stabilized Aqueous Antibody Compositions
JP2014510152A (ja) * 2011-04-07 2014-04-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 粘度が低減された処方物
WO2013003641A2 (en) 2011-06-28 2013-01-03 Inhibrx Llc Serpin fusion polypeptides and methods of use thereof
US10478508B2 (en) * 2012-01-10 2019-11-19 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
US9527890B2 (en) * 2013-06-18 2016-12-27 The Brigham And Womens's Hospital, Inc. FC receptor (FcRn) binding peptides and uses thereof
CN110903398B (zh) * 2014-01-15 2023-08-15 豪夫迈·罗氏有限公司 具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体
US20170190762A1 (en) * 2014-06-11 2017-07-06 Beth Israel Deaconess Medical Center, Inc. Alpha1 -antitrypsin compositions and methods of treating autoimmune diseases
UA127305C2 (uk) 2014-10-27 2023-07-19 ІНГІБРЕКС, Інк. Злитий серпіновий поліпептид і спосіб його застосування
GB201703063D0 (en) * 2017-02-24 2017-04-12 Arecor Ltd Stabilized antibody protein solutions
GB201721846D0 (en) * 2017-12-22 2018-02-07 Arecor Ltd Novel composition

Also Published As

Publication number Publication date
IL305142A (en) 2023-10-01
US20220265788A1 (en) 2022-08-25
AU2022224607A1 (en) 2023-08-31
CN117279624A (zh) 2023-12-22
CA3208704A1 (en) 2022-08-25
EP4294372A1 (en) 2023-12-27
GB202102258D0 (en) 2021-03-31
BR112023016442A2 (pt) 2023-10-10
KR20230147140A (ko) 2023-10-20
WO2022178175A1 (en) 2022-08-25
JP2024506718A (ja) 2024-02-14

Similar Documents

Publication Publication Date Title
Brennan et al. A bioinspired elastin-based protein for a cytocompatible underwater adhesive
JP5730211B2 (ja) ウイルスのアルギニン不活化
Brisson et al. Heat-induced aggregation of bovine lactoferrin at neutral pH: Effect of iron saturation
Van Ruijven-Vermeer et al. Purification of rat fibrinogen and its constituent chains
MX2023009630A (es) Composiciones en disolución acuosa para aumentar la estabilidad de las proteínas diméricas manipuladas genéticamente.
Harvey et al. Isolation and characterization of the storage protein of yam tubers (Dioscorea rotundata)
Gibson et al. A collagen-like glycoprotein from elastin-rich tissues
EP3152230B1 (en) Preparation comprising factor viii and von willebrand factor peptides
WO2021050009A3 (en) Composition of renaturation buffer solution for dimeric proteins and method of renaturation dimeric proteins using the composition thereof
DE602006016133D1 (de) Verwendung von stefin a als gerüstprotein
ES2327208T3 (es) Separacion de fibrinogeno de proteasas de plasma.
US20210207013A1 (en) Protein-based adhesive and its modification
RU2018128613A (ru) Мутированный фактор фон виллебранда
Nissen et al. Limited proteolysis of β2‐microglobulin at Lys‐58 by complement component C1s
MX2022016365A (es) Formulacion de alta concentracion de proteinas de union a antigeno de factor xii.
US20170015885A1 (en) Protein-based adhesives
ES2420535T3 (es) Nuevo proceso para la purificación altamente selectiva de dos proteínas plasmáticas: factor de von willebrand (vwf) y fibronectina (fn).
Kurihara et al. Chemical, immunological and catalytic properties of 2': 3'-cyclic nucleotide 3'-phosphodiesterase purified from brain white matter.
JP2000508644A (ja) 高度に精製された第ｖｉｉｉ因子コンプレックス
CN108064229B (zh) 蛋白质组合物的制造方法和蛋白质组合物
MX2022001166A (es) Metodo para inactivacion viral.
WO2011142529A3 (en) Soluble expression of bulky folded active proteins
AU2018321131B2 (en) Method for virus filtration of von Willebrand Factor
Jansson et al. Isolation and characterization of a 23 kDa protein essential for photosynthetic oxygen evolution
Madaras et al. Purification and characterization of the sand crab (Ovalipes bipustulatus) coagulogen (fibrinogen)